524713-56-2

Usage

Uses

Used in Pharmaceutical Industry:
Dextromethorphan-D3 is used as an internal standard for various applications in the pharmaceutical industry, such as clinical toxicology, urine drug testing, and forensic analysis. It helps in the accurate quantification of Dextromethorphan levels in samples, ensuring the reliability of test results.
Used in Pain Management Testing:
Dextromethorphan-D3 is used as an internal standard in pain management testing to monitor the levels of Dextromethorphan in patients undergoing treatment for pain. This helps in assessing the effectiveness of the treatment and ensuring patient safety.
Used in Isotope Dilution Methods:
Dextromethorphan-D3 is used as an internal standard in isotope dilution methods, which are employed for the accurate quantification of trace amounts of substances in complex samples. This application is particularly useful in research and development, as well as in quality control of pharmaceutical products.
Used in Recreational Drug Testing:
Dextromethorphan-D3 is used as an internal standard in the detection and quantification of Dextromethorphan when it is used recreationally as an illicit drug and hallucinogen. This helps in identifying and monitoring the misuse of the substance, as well as in forensic investigations.

Upstream product

• 524713-55-1 (4bS,8aS,9S)-ethyl 3-methoxy-6,7,8,8a,9,10-hexahydro-5H-9,4b-(epiminoethano)phenanthrene-11-carboxylate 
• 865-50-9 iodomethane-d3 
• 1531-23-3 (+)-3-methoxymorphinan 
• 125-71-3 dextromethorphan 

Relevant academic research and scientific papers

Regioselective and stereospecific deuteration of bioactive aza compounds by the use of ruthenium nanoparticles

An efficient H/D exchange method allowing the deuteration of pyridines, quinolines, indoles, and alkyl amines with D2 in the presence of Ru@PVP nanoparticles is described. By a general and simple procedure involving mild reaction conditions and simple filtration to recover the labeled product, the isotopic labeling of 22 compounds proceeded in good yield with high chemo- and regioselectivity. The viability of this procedure was demonstrated by the labeling of eight biologically active compounds. Remarkably, enantiomeric purity was conserved in the labeled compounds, even though labeling took place in the vicinity of the stereogenic center. The level of isotopic enrichment observed is suitable for metabolomic studies in most cases. This approach is also perfectly adapted to tritium labeling because it uses a gas as an isotopic source. Besides these applications to molecules of biological interest, this study reveals a rich and underestimated chemistry on the surface of ruthenium nanoparticles. Don't just slap a label on it! A regioselective and stereospecific method for the deuteration of nitrogen-containing compounds has been developed on the basis of a C-H activation process triggered by Ru nanoparticles (RuNps). This general and efficient approach to deuterium labeling was applied to 22 compounds, including 8 biologically active substances (see scheme; PVP=polyvinylpyrrolidone). Copyright

COMPOSITIONS AND METHODS THEREOF

Compounds of formula I, (I) or enantiomers thereof, metabolites thereof, derivatives thereof, deuterated derivatives thereof, halogenated derivatives thereof, prodrugs thereof, pharmaceutically acceptable salts thereof, N- oxides thereof, or a combination thereof, processes and intermediates for preparation thereof, compositions thereof, and uses thereof, are provided. Pharmaceutical compositions comprising a compound of formula I and a compound of Formula II: (IIa) (IIb) or enantiomers thereof, metabolites thereof, derivatives thereof, deuterated derivatives thereof, prodrugs thereof, pharmaceutically acceptable salts thereof, N-oxides thereof, or a combination thereof. Compositions and methods for improving the efficacy of DEX, or providing beneficial pharmacokinetic effects to DEX, comprising co-administering a compound of formula I or SARPO, and a compound of Formula II or DEX to a subject in need thereof, and dosage forms, drug delivery systems, methods of treatment thereof.

Morphinan Compounds

This disclosure relates to novel morphinan compounds and their derivatives, pharmaceutically acceptable salts, solvates, and hydrates thereof. This disclosure also provides compositions comprising a compound of this disclosure and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a σ1 receptor agonist that also has NMDA antagonist activity.